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Weight gainWeight gain and metabolic abnormalities are serious side effects associated with the use of several second
generation antipsychotics (SGA). The adipose tissue has been considered a direct SGA target involved in the
development of these adverse effects. Recent studies, mainly using murine cells, have suggested that SGA
increase both adipogenesis of preadipocytes and lipid accumulation in mature adipocytes. However, to date
there has been little research comparing the effects of antipsychotics with different propensities to induce
weight gain on human in vitro models of white adipose tissue neoformation and metabolism. The present
study aimed to investigate the effects of antipsychotics either strongly associated with weight gain, such as
the SGA clozapine and olanzapine, or not, such as the SGA ziprasidone and the classical antipsychotic
haloperidol, on proliferation and adipocyte differentiation of human adipose-derived stem cells (ADSCs) and
lipogenesis in human mature adipocytes. Whereas ziprasidone induced elevated levels of cell death during
adipogenesis and could not be investigated further, we observed that clozapine, olanzapine and haloperidol
had slight stimulatory effects on the transcriptional program of ADSCs adipogenesis. However, the observed
changes in adipocyte-speciﬁc genes were not accompanied by a signiﬁcant increase in triglyceride
accumulation within differentiated adipocytes. Our data also showed that these three antipsychotics
displayed inhibitory effects on the proliferation rates of undifferentiated ADSCs. Regarding mature adipocyte
metabolism, we observed that olanzapine slightly inhibited insulin-stimulated lipogenesis at the highest
concentration used, and haloperidol exerted the strongest inhibitory effects on both basal and insulin-
stimulated lipogenesis. Taken together, our results suggest that a direct and potent effect of clozapine and
olanzapine on adipose tissue biology is not an important mechanism by which these SGA induce metabolic
disturbances in humans. On the other hand, the haloperidol-mediated downregulation of the lipogenic
capacity of human adipose tissue may be a possible mechanism contributing to its lower propensity to induce
serious metabolic side effects.cells; BMI, body mass index; C/
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Second generation antipsychotic drugs (SGA) are considered to
possess superior efﬁcacy in treating both positive and negative
symptoms of schizophrenia compared to ﬁrst-generation antipsy-
chotics (FGA) (e.g. haloperidol) (Bridler and Umbricht, 2003; Keefe et
al., 2006). In addition, these drugs are increasingly being prescribed
for other psychiatric disorders, such as bipolar disorder, autism, and
depression (McDougle et al., 2008; Papakostas and Shelton, 2008;
Pfeifer et al., 2010). However, major side effects of SGA, such as
clozapine and olanzapine, are weight gain and associated metabolic
abnormalities including hyperglycemia, insulin resistance, type II
diabetes, dyslipidemias and cardiovascular diseases (Ananth and
Kolli, 2005; Casey, 2005; Newcomer, 2007; Panagiotopoulos et al.,
2009).
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gain andmetabolic abnormalities are not yet fully understood, several
studies have proposed that these side effects may reﬂect the
antagonist properties of these drugs on central nervous system
pathways involved in the food intake or energy expenditure, such as
histaminergic, serotoninergic/noradrenergic pathways (Deng et al.,
2009; Han et al., 2008; Matsui-Sakata et al., 2005; Opgen-Rhein et al.,
2010; Reynolds et al., 2002). Other studies have also explored a direct
effect of some SGA on the biology of peripheral tissues involved in
body energy homeostasis, such as the adipose tissue.
Increased white adipose tissue mass associated with obesity may
be the function of both, increased adipocyte size, due to lipid
accumulation within fully differentiated adipocytes, and increased
adipocyte number, due to proliferation and adipogenic differentiation
of progenitor cells present in the adipose tissue (Spalding et al., 2008).
Recent reports have suggested that speciﬁc SGA can exert direct
effects on mature rat adipocytes from visceral white adipose tissue,
increasing lipogenesis and decreasing lipolysis to facilitate adipocyte
lipid storage (Minet-Ringuet et al., 2007; Vestri et al., 2006). In
addition, it was proposed that the SGA clozapine and olanzapine
stimulate adipogenesis of the murine preadipocyte cell line 3T3L1
(Yang et al., 2007; 2009). However, there are very limited data
concerning the effects of SGA on cells derived from human adipose
tissue (Hemmrich et al., 2006; Pavan et al., 2009), remaining
substantial uncertainties over these effects.
The present study aimed to extend the ﬁndings of prior studies and
compared the effects of antipsychotics with different weight gain
liabilities, such as the SGA clozapine and olanzapine and the FGA
haloperidol, on proliferation and adipocyte differentiation of human
adipose-derived stem cells (ADSCs), as well as lipogenesis in human
mature adipocytes.
2. Material and methods
2.1. Adipocyte-derived stem cells (ADSCs) isolation and expansion
Liposuction aspirates from abdominal subcutaneous adipose tissue
were obtained from 5 health female subjects (aged 24–38 years;
BMIb25 kg/m2) undergoing cosmetic surgery procedures performed
under general anesthesia (Keck et al., 2010). In order to limit variables
or confounding factors which might affect adipose tissue function,
subjects were devoid of metabolic, endocrine, or cardiovascular
diseases. The study was approved by local ethics committee, and
patients gave their informed consent for using their ADSCs for the
present experiments. ADSCs were isolated by collagenase digestion
(0.075% collagenase in PBS; Sigma type IA collagenase) as described
previously (Zuk et al., 2001), counted using the Trypan blue dye
exclusion assay, and then seeded on plastic tissue culture plates at a
density of 4000 cell/cm2 in DMEM-low glucose medium (Invitrogen)
supplemented with 10% fetal bovine serum (FBS, Invitrogen/Gibco)
and antibiotics (deﬁned as ADSCs growth medium). After achieving a
density of 80–90%, cultures were trypsinized and subcultured at a 1:4
ratio. All tests were performed at passage 4.
2.2. Immunophenotyping
ADSC populations used in the experiments were analysed with
speciﬁc cell surface markers to evaluate homogeneity. Cells were
harvested with trypsin, centrifuged at 500 g for 5 min, washed with
phosphate-buffered saline (PBS), and resuspended in PBS. Cells
(1×105cells/tube) were then incubated at 4 °C for 30 min with the
following antibodies: CD29-PE-Cy5, CD90 (Thy-1)-PE-Cy5, CD45-
FITC, CD31-PE, CD105 (SH2) and CD73 (SH3/4) (Becton Dickinson).
After a second wash with PBS, samples incubated with unconjugated
primary antibodies were incubated with anti-mouse-PE secondary
antibody (Guava Technologies) for additional 15 min at 4 °C. Finally,the cell suspension was washed with PBS, and 105 labeled cells were
acquired with an EasyCyte Flow cytometer (Guava Technologies).
Control samples were incubated with PBS instead of primary
antibody, followed by incubation with anti-mouse-PE secondary
antibody. All the plots generated were analysed with Guava
ExpressPlus software (Guava Technologies).
2.3. Adipocyte differentiation and pharmacological treatment
To induce adipocyte differentiation, ADSCs were grown to
conﬂuence (deﬁned as day 0) and then cultured in adipogenic
induction medium [DMEM high glucose (25 mM) supplemented with
10% FBS, antibiotics, 1 μM dexamethasone (Sigma), 200 μM indo-
methacin (Sigma), 0.5 mM IBMX (Sigma), and 10 μg/ml insulin
(Sigma)] for 14 days, which represents the usual time needed to
acquire a fully differentiated phenotype. The inﬂuence of the different
antipsychotic drugs on adipogenesis was tested by supplementing the
differentiation medium with clozapine (Sigma, MO, USA), olanzapine
(Toronto Research Chemicals, Toronto, Canada), ziprasodone (Pﬁzer
inc., NY, USA) or haloperidol (Sigma, MO, USA) at different
concentrations during the ﬁrst stage of differentiation (either for
the ﬁrst 3 days or for the ﬁrst 7 days during differentiation). The
antipsychotic drugs were used at doses similar to their therapeutic
plasma concentrations [considered to be in the range of 0.6 to 1 μM
clozapine (Broich et al., 1998); 0.07–0.2 μM olanzapine (Bergemann
et al., 2004; Robinson et al., 2006); 0.1–0.25 μM ziprasidone (Vogel et
al., 2009); and 0.05 μM haloperidol (Coryell et al., 1998)], at doses 10-
fold higher than those (10 μM clozapine; 2 μM olanzapine; 2.5 μM
ziprasidone; 0.5 μM haloperidol), or at 20, 30, 40 and 100 μM. Control
cells were treated with DMSO alone (solvent used to dissolve the
drugs) and no effect of this solvent on adipogenesis was observed
(data not shown).
2.4. Cell viability analysis during adipogenic differentiation
Cells were plated into 12-well cell culture plates (1.5×104cells/
well) and grown to conﬂuence (day 0). The cells were then cultured in
adipogenic induction medium supplemented with DMSO (control) or
clozapine, olanzapine, ziprasidone or haloperidol at different concen-
trations, as described above. On day 14 after induction, the cells were
trypsinized, stained with trypan blue and counted with an Automated
Cell Counter (Invitrogen). The experiment was done in triplicates for
each antipsychotic treatment and each cell line. The data were
normalized to cell number of DMSO-treated samples.
2.5. RNA extraction, reverse transcription reactions and quantitative real
time PCR
Cells for expression analysis were grown in 75 cm2 plastic culture
ﬂasks. Total RNA from conﬂuent undifferentiated ADSCs (day 0), and
from cells cultured in adipogenic induction medium supplemented or
not (DMSO alone) with the antipsychotics was isolated using
Nucleospin RNA kit (Macherey-Nagel). RNA quality and concentration
were accessed respectively by 1.5% agarose gel electrophoresis and
NanodropND-1000. Complementary DNA (cDNA)was produced from
1.5 μg of total RNA using Superscript II reverse transcription kit
(Invitrogen). Quantitative real-time PCR was performed using
approximately 15 ng of cDNA and SYBR Green PCR master mix in an
ABI Prism 7500 system (Applied Biosystems). Primers were designed
using Primer Express software v2.0 (Applied Biosystems) and the
ampliﬁcation efﬁciency (E) of each primer was calculated according to
the equation E=10 (−1 / slope). The expression data of the adipocyte-
speciﬁc transcripts C/EBPβ, PPARγ2 and LPL, as well as an unrelated
transcript DDX58, were determined by relative quantiﬁcation in
comparison to four endogenous controls HMBS, HPRT1, GAPDH and
SDHA. GeNorm v3.4 was used to determine the most stable controls
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Fig. 1. Flow cytometric analysis of human adipose-derived mesenchymal stem cells
(ADSCs). ADSCs cultured for four passages express characteristic mesenchymal cell
surface markers. Data represent means±SE (n=4).
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2002). The expression data is given by the ratio between each
transcript ΔΔCt (EΔCT) and NF. All cDNA samples were run in
triplicates, and the threshold suggested by the instrument software
was used to calculate Ct. Results were normalized to DMSO-treated
control (1.0).
2.6. Oil red O staining and measurement of triglyceride content
Cells for quantitation of lipid accumulation were cultured in 12-
well cell culture plates and, for each experiment, three wells per
condition were used. For Oil Red O staining, following adipogenic
differentiation for 14 days, cells were washed with PBS, ﬁxed in 4%
formaldehyde for 30 min and then stained with 0.6% (w/v) Oil Red O
solution (60% isopropanol, 40% water) for 1 h at room temperature.
Cells were them washed with 60% isopropanol three times to remove
unbound dye and photographed. Stained Oil Red O was also eluted
with 4% NP-40 in isopropanol (v/v) and quantiﬁed by measuring the
optical absorbance at 490 nm. Oil Red O staining of undifferentiated
ADSCs grown in parallel culture served as the blank sample for this
assay.
Cellular triglyceride content was determined by the enzyme-
colorimetric method, using a commercially available Kit (Laborlab).
Results were normalized by the number of cells present in each well
and were expressed as percent of control (DMSO).
2.7. Cell-proliferation analysis
A concentration of 4000 viable cells/cm2 was plated to eachwell of
a 12-well cell culture plate in ADSCs growth medium. After 24 h,
when total cell adhesion was veriﬁed, the medium was changed for
ADSCs growth medium supplemented or not with DMSO (control), or
clozapine (20 μM, 30 μM), olanzapine (20 μM, 40 μM, 100 μM), and
haloperidol (20 μM, 40 μM). The cells were trypsinized at 0, 24, 48 and
72 h after plating, stained with trypan blue and counted using Guava
EasyCyte Flow Cytometer (Guava Technologies). The experiment was
done in triplicates for each time point and each cell line.
2.8. Lipogenesis measurement
Adipocytes from freshly excised abdominal subcutaneous adipose
tissue of other 5 health female patients (aged 32–41 years;
BMIb25 kg/m2) undergoing liposuction procedures performed
under general anesthesia were isolated by enzymatic digestion
(0.075% colagenase type II), suspended in Krebs/Ringer/phosphate
buffer (pH 7.4) containing 1% BSA and 2 mM glucose (to a ﬁnal
concentration of 1×106cells/mL), and saturated with a gas mixture of
CO2 5%/O2 95%. Aliquots of 450 μL were then pipetted into
polypropylene tubes containing [U-14C]-D-glucose (0.1 μCi/tube),
DMSO or clozapine, olanzapine and haloperidol (40 μM and 100 μM)
in the presence and absence of 10 nM insulin for 3 h at 37 °C in an
orbital shaking water bath. After this period, the incubation medium
was acidiﬁed with 200 μL of 8N H2SO4 to rupture cells, and 2.5 mL of
Dole's reagent (isopropanol : n-heptane : H2SO4, 4:1:0.25 vol/vol/vol)
were added for lipid extraction. Radioactivity in the organic phasewas
determined by liquid scintillation counting and represented glucose
incorporation into lipid. Activities of lipogenesis were normalized to
protein concentrations and were expressed as percentage of control
(DMSO). Lipogenesis was increased with maximal insulin concentra-
tion 1.3 to 1.5 fold (data not shown).
2.9. Cell cytotoxicity analysis during lipogenesis measurement (XTT-
colorimetric assay)
Antipsychotic-induced cytotoxicity during in vitro lipogenesis was
measured by means of a colorimetric XTT viability assay (CellProliferation Kit II-XTT, Roche) in accordance with the instructions
of the supplier. Brieﬂy, adipocytes from two out of the ﬁve female
subjects described above were pipetted into microcentrifuge tubes (at
a density of 1×106cells/tube) and treated as for the lipogenesis
experiment. XTT solution was added into each tube to give a ﬁnal
concentration of 0.3 mg/mL, and the cells were then incubated for 3 h
at 37 °C. After the reaction, resulting formazan dye was quantiﬁed
with an ELISA plate reader at 450 nM whereas the absorbance
correlated directly with the number of viable cells. All incubations
were performed in triplicate with inclusion of a positive control
(mechanical cell lysis) and a blank sample (containingmedia, XTT but
no cells).
2.10. Statistical analysis
Data are reported as the means±standard deviation (SD).
Comparison between culture conditions was determined using
Student's t-test, where pb0.05 was considered statistically signiﬁcant.
3. Results
3.1. Isolation and characterization of human adipocyte-derived stem
cells (ADSCs)
ADSCs were obtained from human abdominal subcutaneous
adipose tissue samples (n=5 female donors) and cultured for four
passages. To characterize the homogeneity of the samples, they were
subjected to ﬂow cytometric analysis. We observed that these cells
expressed the mesenchymal stem cell markers CD105 and CD73, the
cell adhesion markers CD29 and CD90, but did not express the
hematopoietic cell marker CD45 and the endothelial cell marker CD31
(Fig. 1). These ﬁndings suggest that we have isolated a relatively
homogeneous population of mesenchymal cells.
All ADSC samples subjected to adipogenic differentiation showed
marked alteration in cell morphology and accumulation of lipid
droplets that could be stained by the lipophilic dye Oil Red O, which
were completely absent in the undifferentiated cells (Fig. 2). In
addition, real-time PCR analysis revealed that on day 3 of the
differentiation process the expression levels of the key adipogenic
transcription factors C/EBPβ and PPARγ2 were signiﬁcantly increased
compared to undifferentiated ADSCs (day 0); and that on day 14 after
induction the expression levels of PPARγ2 and LPL, an adipocyte-
speciﬁc enzyme related to triglyceride metabolism that appears later
on in the differentiation process, were also largely increased
compared to undifferentiated ADSCs (Fig. 3).
3.2. Effects of antipsychotic drugs on the viability of ADSCs during
adipogenic differentiation
We ﬁrst examined whether clozapine, olanzapine, ziprasidone or
haloperidol at different concentrations exert cytotoxic effects on
BA
Fig. 2. Morphological characteristics of undifferentiated ADSCs and differentiated adipocytes derived from ADSCs. (A) Undifferentiated ADSCs, under phase contrast microscopy,
display a ﬂattened ﬁbroblast-like morphology and were not stained by Oil red O solution. (B) Oil red O staining showed that differentiated adipocytes (on day 14 of differentiation
induction) accumulate lipid droplets.
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tions used were similar to those detectable in the plasma of treated
patients (1 μM clozapine, 0.2 μM olanzapine, 0.2 μM ziprasidone, and
0.05 μM haloperidol), or were 10-fold higher or more (20 to 100 μM)
than those.
We observed that ziprasidone induced elevated levels of cell death
at all concentrations after few hours in culture, and it was not further
investigated in our experiments (data not shown). Cell exposure to
concentrations higher than 30 μM of clozapine and 40 μM of
haloperidol also induced cytotoxicity after 2–3 days in culture. On
the other hand, olanzapine at all concentrations tested did not appear
to have any effect on cell viability (Fig. 4). Therefore, concentrations
up to 30 μM of clozapine, 100 μM of olanzapine and 40 μM of
haloperidol displayed no signiﬁcant effect on cell viability until theA
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Fig. 3. Gene expression of early and late markers of adipocyte differentiation. Conﬂuent
ADSCs were induced to differentiate into adipocytes and the expression of (A) C/EBPβ
and PPARγ2, and (B) PPARγ2 and LPL was analysed by quantitative real-time at days
0 and 3 and/or 14 after induction respectively. Levels of gene expression are shown
relative to their levels in unexposed undifferentiated ADSCs (day 0, control=1). Data
represent means±SE (n=4–5). *Pb0.05 compared with control respectively.end of the differentiation period and were used in subsequent
experiments.
3.3. Effects of antipsychotic drugs on the adipocyte differentiation
program of ADSCs
We next examined the effects of clozapine, olanzapine and
haloperidol on the control of the adipocyte differentiation program.
On day 3 of the differentiation process, we observed that administra-
tion of these drugs at doses similar to their therapeutic plasma
concentrations or at doses 10-fold greater than those displayed no
signiﬁcant effects on the expression of C/EBPβ and PPARγ2. On the
other hand, administration of these drugs at higher doses induced a
slight dose-dependent increase in the expression of these genes
(Fig. 5A). Similar results were observed on day 14 after induction, in
which increases in the expression levels of PPARγ2 and LPL were also
observed in a dose-dependent manner but only at higher antipsy-
chotic dosages (Fig. 5B). As an internal control, no signiﬁcant change
in the expression pattern of a functionally unrelated gene,DDX58, was
detected in the presence of the antipsychotic drugs (data not shown).
These results indicate that all three antipsychotics at doses higher
than their therapeutic plasma concentrations induced a dose-
dependent increase in adipogenesis-related mRNAs.
3.4. Effects of antipsychotics on cellular triglyceride accumulation
To determine whether the observed increase in the expression of
adipocyte-related genes was also accompanied by triglyceride*
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Fig. 4. Effects of antipsychotic drugs on the viability of the cells during adipogenic
differentiation. Cell number after treatment of ADSCs for 14 days with adipogenic
induction medium supplemented with DMSO (control) or indicated concentrations of
clozapine, olanzapine, and haloperidol. All values were normalized by DMSO treatment
(100%) and represent the means±SE (n=3). Δ = Doses compatible with that
detectable in the plasma of treated patients or 10-fold higher than those. *Pb0.05
compared with control.
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Fig. 5. Effect of clozapine, olanzapine and haloperidol on the expression of adipogeneic genes. Conﬂuent ADSCs were induced to differentiate into adipocytes with or without the
indicated concentration of the antipsychotic drugs during the ﬁrst three days of the differentiation process. At day 3 and 14, total RNAwas extracted and the expression of (A) C/EBPβ
and PPARγ2, and (B) PPARγ2 and LPLwas analysed by quantitative real-time PCR respectively. Relative mRNA expression was calculated as fold increase of the control group which
was induced to differentiation in the presence of solvent only (DMSO). Data represent means±SE (n=4–5). Δ= Doses compatible with that detectable in the plasma of treated
patients or 10-fold higher than those. Pb0.05, **Pb0.01, ***Pb0.001 compared with control respectively.
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staining were performed on day 14 after induction. We observed
that triglyceride content of differentiated adipocytes did not change
signiﬁcantly in response to the antipsychotics (Fig. 6). In accordance
with these results, OD value of Oil Red O eluted solution, which
represents lipid droplet accumulation in the cytoplasm, did not
increase signiﬁcantly in the antipsychotic treated samples (data not
shown). Therefore, although addition of clozapine (20 and 30 μM),
olanzapine (20, 40 and 100 μM) and haloperidol (20 and 40 μM) in the
differentiation medium induced a comparable increase in the levels of
adipocyte-speciﬁc genes, robust increase in intracellular lipid levels
compared with control was not observed. In order to verify whether a
longer antipsychotic treatment period had implications in the
differentiation potential of ADSCs, the antipsychotic drugs (at the0%
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Fig. 6. Effect of clozapine, olanzapine and haloperidol on cell triglyceride accumulation.
Conﬂuent ADSCs were induced to differentiate into adipocytes in the absence (DMSO)
and presence of the indicated concentration of the antipsychotic drugs during the ﬁrst
three days of induction initiation. The doses used were those previously determined to
induce the expression of adipocyte-speciﬁc genes. The content of triacylglycerol was
measured at the end of the differentiation process (day 14) by a commercially available
test. All values were normalized by DMSO treatment (100%) and represent means±SE
(n=4–5).same concentrations speciﬁed previously) were also added for the
ﬁrst 7 days during differentiation and no differences were observed
between treatments (data not shown).
3.5. Effects of antipsychotics on proliferation of undifferentiated ADSCs
Effects of clozapine (20 and 30 μM), olanzapine (20, 40 and
100 μM) and haloperidol (20 and 40 μM) exposure on the prolifer-
ation rates of ADSCs were also assessed. Under our experimental
conditions, whereas DMSO (control) exerted no effects on ADSCs
expansion, the three antipsychotic drugs at all concentrations tested
exerted inhibitory effects on ADSCs proliferation, observed by a strong
decrease in cell number soon after the beginning of antipsychotic
treatment (data not shown).
3.6. Effects of antipsychotic drugs on lipogenesis in human mature
adipocytes
Effects of clozapine, olanzapine and haloperidol on basal and
insulin-stimulated lipogenesis were also assessed by measuring
incorporation of labeled 14C-glucose into total lipids. In order to
obtain a clearcut effect and to be able to compare our results with
those of a previous study using isolated rat adipocytes, the
antipsychotics were used at 40 and 100 μM. We ﬁrst ensured that at
these concentrations the antipsychotics did not exert cytotoxic effects
on human mature adipocytes. At the end of the experiment,
microscopic analysis of the cell suspensions did not reveal any
observable cell lysis. In addition, cell viability assessed by the XTT-
colorimetric assay indicated that the antipsychotics in these dosages
did not induce cytotoxicity during the incubation period used in the
experiment (data not shown).
We observed, under our experimental conditions, no signiﬁcant
effects of clozapine on basal and insulin-stimulated lipogenesis
compared to control (cells treated with DMSO-100%) (Fig. 7). On
the other hand, we observed that olanzapine, at the highest
concentration analysed (100 μM), signiﬁcantly inhibited insulin-
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Fig. 7. Effect of clozapine, olanzapine and haloperidol on basal and insulin-stimulated lipogenesis in adipocytes. Human adipocytes were incubated with DMSO or the antipsychotic
drugs (at 40 and 100 μM) in the absence (basal) and presence of 10 nM insulin. Rates of lipogenesis were assessed as 14C-glucose label incorporated into lipids. All values were
normalized by DMSO treatment (100%) and represent means±SE (n=5). *Pb0.05, **Pb0.01 vs. control respectively.
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haloperidol, at both concentrations, exerted the strongest inhibitory
effects on both basal and insulin-stimulated de novo lipogenesis
(approximately 15% and 17% at 40 μM and 12% and 24% at 100 μM
respectively) (Fig. 7). Whereas the effects of clozapine and olanzapine
on mature adipocytes are not correlated with their greater propensity
to induce adiposity, our results clearly suggest that haloperidol
reduces both basal and maximal insulin-stimulated rates of lipogen-
esis in human adipocytes in vitro.
4. Discussion
A clear understanding of themechanisms involved in SGA-induced
weight gain and metabolic disturbances is of great importance in
clinical practice because it can help guide therapeutic decisions as
well as the design of new treatments to reduce the serious metabolic
side effects of these largely prescribed drugs.
It has recently been proposed that a direct effect of speciﬁc SGA on
adipose tissue could provide an alternative, but not necessarily
exclusive, mechanism for the adverse metabolic outcomes (Hemmrich
et al., 2006; Minet-Ringuet et al., 2007; Pavan et al., 2009; Vestri et al.,
2006; Victoriano et al., 2010; Yang et al., 2007; 2009). The present study
focused on the effects of antipsychotics with different binding proﬁles
and weight gain liabilities on the proliferation and differentiation of
ADSCs and lipogenesis in human mature adipocytes in vitro.
Our results showed that the SGA clozapine and olanzapine had
slight stimulatory effects on genes considered as early or late markers
of adipose tissue differentiation. Our data also showed, for the ﬁrst
time, that haloperidol exhibited similar stimulatory effects on the
expression of adipocyte-speciﬁc genes. However, these effects were
observed to occur only in those cells receiving antipsychotic doses
higher than that observed in the plasma of treated patients.
Interestingly, the activation of the transcriptional program of
adipogenesis in the cells treated with these three antipsychotic
drugs was not accompanied by a signiﬁcant increase in triglyceride
(TG) accumulation within differentiated adipocytes. Although the
reasons for these alterations in gene expression remain to be
determined, our results suggest that the observed increase in
expression of the adipocyte-speciﬁc genes is not sufﬁcient to inducesigniﬁcant TG accumulation, and that the differing degrees of weight
gain upon use of clozapine, olanzapine and haloperidol are not related
to different potential of these drugs to induce adipogenesis of
progenitor cells present in the adipose tissue.
It is important to note that two previous studies using cultured
human adipocyte progenitor cells reported that the addition of
clozapine and olanzapine during the initial stages of adipogenic
differentiation process induced a small increase in TG accumulation
(about 1.3 fold compared to control) within differentiated cells
(Hemmrich et al., 2006; Pavan et al., 2009). Whereas, Hemmrich et
al. (2006) used similar concentrations of clozapine to those we used,
Pavan et al. (2009) used a much higher concentration of clozapine
and olanzapine. Thus, despite the methodological differences, the
studies performed so far suggest that clozapine and olanzapine did
not potently increase adipogenesis of human adipocyte precursor
cells, even at very high dosages. In addition, our ﬁndings suggest
that enhanced proliferation of human ADSCs may also not be an
important mechanism by which the SGA alter adipose tissue
biology.
Regarding the effects of the antipsychotics on human mature
adipocytes, our data revealed that whereas the SGA clozapine did not
exert any signiﬁcant effect on the rates of lipogenesis in isolated
human adipocytes, olanzapine signiﬁcantly inhibited insulin-stimu-
lated lipogenesis at the highest concentration used. These results
suggests that the effects of olanzapine on central nervous system
pathways involved in regulation of energy balance and adiposity
might overcame its possible direct inhibitory effect on the lipogenic
capacity of human adipocytes. It is noteworthy that Vestri et al.
(2006), after execution of a protocol very similar to the one we used,
observed that clozapine and olanzapine (100 μM) enhanced both
basal and insulin-induced lipogenesis in isolated rat adipocytes.
Therefore, these ﬁndings suggest that the SGA might show species-
speciﬁc effects, and this point should be taken into consideration in
studying their adverse effects. Interestingly, we observed that
haloperidol exerted the strongest inhibitory effects on both basal
and insulin-stimulated rates of lipogenesis in isolated human
adipocytes. Therefore, although further investigations are required
to determine the clinical relevance of these ﬁndings, it is tempting to
speculate that the haloperidol-induced reduction in lipogenic capacity
1890 A.L. Sertié et al. / Progress in Neuro-Psychopharmacology & Biological Psychiatry 35 (2011) 1884–1890of human adipose tissue may be a mechanism contributing to its
lower propensity to induce weight gain and metabolic abnormalities.
5. Conclusions
Taken together, the results obtained from the experiments
conducted with these in vitromodels suggest that a potent and direct
effect of clozapine and olanzapine on adipose tissue development and
metabolism is not an important mechanism by which these SGA
induce metabolic disturbances in humans. We cannot rule out that
these SGA have different effects on visceral adipose tissue, which is
known to exhibit different biological properties compared to
subcutaneous adipose tissue. In addition, our ﬁndings also point to a
possible mechanism contributing to haloperidol's lower liability to
cause weight gain in humans, via inhibition of the lipogenic capacity
of adipocytes. Finally, our data suggest that, due to species related
differences, the use of cells derived from human adipose tissue
represents a more biologically relevant model than murine cells for
studying the effects of antipsychotic drugs on this tissue. It will be a
major challenge to investigate in vivo the exact effects of these
antipsychotic drugs on human adipose tissue development and
metabolism.
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